Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Review Article

Comprehensive Review of Ethnopharmacological and Phytochemical Aspects of Nutraceuticals in Psychiatric Disorders

Author(s): Samir Patel*, Niraj Vyas, Alkesh Patel, Umang Shah, Manan Raval, Mehul Patel and Archita Patel

Volume 11, Issue 1, 2022

Published on: 28 July, 2022

Page: [30 - 42] Pages: 13

DOI: 10.2174/2211556011666220510141329

Price: $65

Abstract

Ageing comes with degeneration in many biological activities like impairment of cognition, intelligence, attention, and memory. The decline in all those mental capabilities would be due to the abnormal changes in neuronal architecture with increasing age, chronic oxidative stress, inflammatory state of the tissue, and nutritional deficiency. Nootropics or smart drugs enhance memory, attention, creativity, and cognitive performance by affecting the synthesis and receptor binding of neurotransmitters in the brain, especially dopamine, serotonin, gamma-aminobutyric acid, glutamate, and acetylcholine. Nootropics have shown their positive effects in Parkinson’s, autism, Alzheimer’s, and Huntington's disease, where impaired memory is the primary concern. The synthetic class of nootropics has limitations and reported exacerbation of other brain disorders (off label effects) or therapeutic failure in some instances. Nutraceuticals are dietary derived vitamins, minerals, herbal products, proteins, marine products, and probiotics. The health benefits derived from nutraceuticals are increased brain blood flow, reduced inflammation in nervous tissues, detoxified toxins from the brain, balanced neurotransmitter turnover rate, corrected neuronal and receptor damages and prompt synaptic transmission, good antioxidant properties and power of improving neuroplasticity of the brain that combats neurodegeneration. The demand for effective nootropics will remain high as the number of cases is being increased tremendously.

Keywords: Nutraceuticals, nootropics, neurodegeneration, memory, neurotransmission, synaptic plasticity, abuse.

Graphical Abstract

[1]
Crespo-Bujosa HB, Héctor B, Rodríguez RL, Nootropics RL. Phytochemicals with neuroprotective and neurocognitive enhancing properties. Eurorean J Clin Exp Med 2019; 17(3): 250-5.
[http://dx.doi.org/10.15584/ejcem.2019.3.9]
[2]
Talokar SS, Vakhariya RR, Salunkhe VR, Magdum C. A review on nootropics and nutraceuticals: The missile for ageing. Int Res J Pharm 2017; 8(4): 1-4.
[http://dx.doi.org/10.7897/2230-8407.080438]
[3]
Tortora GJ. D B Principles of Anatomy and Physiology. 12th ed. Hoboken, New Jersey: John Wiley & Sons 2009.
[4]
Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J Neurosci 1996; 16(6): 2027-33.
[http://dx.doi.org/10.1523/JNEUROSCI.16-06-02027.1996] [PMID: 8604047]
[5]
Navarro QE, Navarro QR, Ahmad M, et al. Cell signaling in neuronal stem cells. Cells 2018; 7(7): 75.
[http://dx.doi.org/10.3390/cells7070075] [PMID: 30011912]
[6]
Suliman NA, Mat TCN, Mohd MMA, Adenan MI, Hidayat BMT, Basir R. Establishing natural nootropics: Recent molecular enhancement influenced by natural nootropic. Evidence-based Complement Altern Med 2016. 2016.
[7]
Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 2000; 31(9): 2112-6.
[http://dx.doi.org/10.1161/01.STR.31.9.2112] [PMID: 10978039]
[8]
Petroff OAC. GABA and glutamate in the human brain. Neuroscientist 2002; 8(6): 562-73.
[http://dx.doi.org/10.1177/1073858402238515] [PMID: 12467378]
[9]
Hasan MT, Hernández-González S, Dogbevia G, et al. Role of motor cortex NMDA receptors in learning-dependent synaptic plasticity of behaving mice. Nat Commun 2013; 4(1): 2258.
[http://dx.doi.org/10.1038/ncomms3258] [PMID: 23978820]
[10]
Harkany T, Abrahám I, Timmerman W, et al. β-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000; 12(8): 2735-45.
[http://dx.doi.org/10.1046/j.1460-9568.2000.00164.x] [PMID: 10971616]
[11]
Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease: Therapeutic implications. CNS Drugs 2003; 17(9): 641-52.
[http://dx.doi.org/10.2165/00023210-200317090-00004] [PMID: 12828500]
[12]
Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 1995; 20(2): 250-67.
[http://dx.doi.org/10.1016/0165-0173(94)00014-G] [PMID: 7795658]
[13]
Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 2005; 30(12): 2135-43.
[http://dx.doi.org/10.1038/sj.npp.1300761] [PMID: 15956997]
[14]
Greenamyre JT, Penney JB, Amato CJD, Young AB. Dementia of the Alzheimer’ s Type: Changes in Hippocampal L- [ 3H] glutamate binding. J Neurochem 1987; 48(2): 543-51.
[15]
Ułas J, Brunner LC, Geddes JW, Choe W, Cotman CW. N-methyl-D-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer’s disease. Neuroscience 1992; 49(1): 45-61.
[http://dx.doi.org/10.1016/0306-4522(92)90075-D] [PMID: 1407551]
[16]
Singh HK, Neuropsychopharmacological DB. Effects of the ayurvedic nootropic Bacopa Monniera Linn.(Brahmi). Indian J Pharmacol 1997; 27(5): 359.
[PMID: 31831931]
[17]
Esiri MM, Wilcock GK. The olfactory bulbs in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1984; 47(1): 56-60.
[http://dx.doi.org/10.1136/jnnp.47.1.56] [PMID: 6693914]
[18]
Sisodia SS. Alzheimer’s disease: Perspectives for the new millennium. J Clin Invest 1999; 104(9): 1169-70.
[http://dx.doi.org/10.1172/JCI8508] [PMID: 10545514]
[19]
Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37(6): 925-37.
[http://dx.doi.org/10.1016/S0896-6273(03)00124-7] [PMID: 12670422]
[20]
Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020; 27(1): 18.
[http://dx.doi.org/10.1186/s12929-019-0609-7] [PMID: 31906949]
[21]
Stadelmann C, Deckwerth TL, Srinivasan A, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer’s disease. Evidence for apoptotic cell death. Am J Pathol 1999; 155(5): 1459-66.
[http://dx.doi.org/10.1016/S0002-9440(10)65460-0] [PMID: 10550301]
[22]
Moriguchi S, Han F, Shioda N, et al. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice. J Neurochem 2009; 110(1): 170-81.
[http://dx.doi.org/10.1111/j.1471-4159.2009.06122.x] [PMID: 19457128]
[23]
Torres-Aleman I. Serum growth factors and neuroprotective surveillance: Focus on IGF-1. Mol Neurobiol 2000; 21(3): 153-60.
[http://dx.doi.org/10.1385/MN:21:3:153] [PMID: 11379797]
[24]
Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: Review and clinical implications. Neurosci Biobehav Rev 2000; 24(8): 855-72.
[http://dx.doi.org/10.1016/S0149-7634(00)00040-3] [PMID: 11118610]
[25]
Park CR. Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001; 25(4): 311-23.
[http://dx.doi.org/10.1016/S0149-7634(01)00016-1] [PMID: 11445137]
[26]
Amadio M, Govoni S, Alkon DL, Pascale A. Emerging targets for the pharmacology of learning and memory. Pharmacol Res 2004; 50(2): 111-22.
[http://dx.doi.org/10.1016/j.phrs.2004.01.003] [PMID: 15177298]
[27]
Storm-Mathisen J, Danbolt NC. Localization of glutamate and its membrane transport proteins. In: CNS Neurotransmitters and Neuromodulators. Glutamate 1995; pp. 1-16.
[28]
Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003; 140(1-2): 1-47.
[http://dx.doi.org/10.1016/S0166-4328(02)00272-3] [PMID: 12644276]
[29]
Dure LS IV, Young AB. The distribution of glutamate receptor subtypes in mammalian central nervous system using quantitative in vitro autoradiography. CNS Neurotransmitters and Neuromodulators. Glutamate 1995; pp. 83-94.
[30]
Bhattacharya SK, Upadhyay SN, Jaiswal AK. Effect of piracetam on electroshock induced amnesia and decrease in brain acetylcholine in rats. Indian J Exp Biol 1993; 31(10): 822-4.
[PMID: 8276434]
[31]
Kirazov E, Kirazov L, Bigl V, Schliebs R. Ontogenetic changes in protein level of amyloid precursor protein (APP) in growth cones and synaptosomes from rat brain and prenatal expression pattern of APP mRNA isoforms in developing rat embryo. Int J Dev Neurosci 2001; 19(3): 287-96.
[http://dx.doi.org/10.1016/S0736-5748(01)00012-0] [PMID: 11337197]
[32]
Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 2003; 70(1): 1-32.
[http://dx.doi.org/10.1016/S0301-0082(03)00089-3] [PMID: 12927332]
[33]
Le Merrer J, Noguès X. Cognitive neuropharmacology: New perspectives for the pharmacology of cognition. Pharmacol Res 2000; 41(5): 503-14.
[http://dx.doi.org/10.1006/phrs.1999.0642] [PMID: 10753548]
[34]
Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res 2001; 44(5): 353-61.
[http://dx.doi.org/10.1006/phrs.2001.0893] [PMID: 11712865]
[35]
Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr. Insulin in the brain: A hormonal regulator of energy balance. Endocr Rev 1992; 13(3): 387-414.
[PMID: 1425482]
[36]
O’Malley D, Shanley LJ, Harvey J. Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology 2003; 44(7): 855-63.
[http://dx.doi.org/10.1016/S0028-3908(03)00081-9] [PMID: 12726817]
[37]
Norambuena A, Wallrabe H, McMahon L, et al. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer’s disease. Alzheimers Dement 2017; 13(2): 152-67.
[http://dx.doi.org/10.1016/j.jalz.2016.08.015] [PMID: 27693185]
[38]
Kamila SMN. Cell line toxicity study and pharmacological screening of effective nootropic herbal formulation in rat. Indian J Nat Prod Resour 2019; 10(1): 23-30.
[39]
Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl) 1990; 101(2): 147-59.
[http://dx.doi.org/10.1007/BF02244119] [PMID: 2190256]
[40]
Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 1991; 194(1): 71-6.
[http://dx.doi.org/10.1016/0014-2999(91)90125-A] [PMID: 2060594]
[41]
Dhingra D, Kumar V. Memory-enhancing activity of palmatine in mice using elevated plus maze and morris water maze. Adv Pharmacol Sci 2012. 2012
[http://dx.doi.org/10.1155/2012/357368]
[42]
Ghosh A, Dhumal VR, Tilak AV, Das N, Singh A, Bondekar AA. Evaluation of nootropic and neuroprotective effects of low dose aspirin in rats. J Pharmacol Pharmacother 2011; 2(1): 3-6.
[http://dx.doi.org/10.4103/0976-500X.77079] [PMID: 21701638]
[43]
Kumar SS, Saraswathi P, Vijayaraghavan R. Effect of bacopa monniera on cold stress induced neurodegeneration in hippocampus of wistar rats: A histomorphometric study. J Clin Diagn Res 2015; 9(1): AF05-7.
[http://dx.doi.org/10.7860/JCDR/2015/10199.5423] [PMID: 25737970]
[44]
Dirnagl U, Kaplan B, Jacewicz M, Pulsinelli W. Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J Cereb Blood Flow Metab 1989; 9(5): 589-96.
[http://dx.doi.org/10.1038/jcbfm.1989.84] [PMID: 2674168]
[45]
Shinomol GK. Muralidhara. Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice. Neurotoxicology 2008; 29(6): 948-57.
[http://dx.doi.org/10.1016/j.neuro.2008.09.009] [PMID: 18930762]
[46]
Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010; 16(7): 753-9.
[http://dx.doi.org/10.1089/acm.2009.0342] [PMID: 20590480]
[47]
Tabassum N, Rasool S, Malik Z, Ahmad F. Natural cognitive enhancers. J Pharm Res Vol 2012; 5(1): 153-60.
[48]
Matthews EA, Dietrich D. Buffer mobility and the regulation of neuronal calcium domains. Front Cell Neurosci 2015; 9(FEB): 48.
[http://dx.doi.org/10.3389/fncel.2015.00048] [PMID: 25750615]
[49]
Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol 1997; 53(2): 135-40.
[http://dx.doi.org/10.1016/S0006-2952(96)00463-7] [PMID: 9037245]
[50]
Cicero AFG, Colletti A. Nutraceuticals active on central nervous system. Handb. Nutraceuticals Clin 2018; pp. 1-23.
[51]
Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease. Ann Neurosci 2017; 24(2): 111-22.
[http://dx.doi.org/10.1159/000475900] [PMID: 28588366]
[52]
Cicero AF, Bove M, Colletti A, et al. Short-term impact of a combined nutraceutical on cognitive function, perceived stress and depression in young elderly with cognitive impairment: A pilot, double-blind, randomized clinical trial. J Prev Alzheimers Dis 2017; 4(1): 12-5.
[PMID: 29188854]
[53]
Miraj S, Alesaeidi S. A systematic review study of therapeutic effects of Matricaria recuitta chamomile (chamomile). Electron Physician 2016; 8(9): 3024-31.
[http://dx.doi.org/10.19082/3024] [PMID: 27790360]
[54]
Chang SM, Chen CH. Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: A randomized controlled trial. J Adv Nurs 2016; 72(2): 306-15.
[http://dx.doi.org/10.1111/jan.12836] [PMID: 26483209]
[55]
Socci V, Tempesta D, Desideri G, De Gennaro L, Ferrara M. Enhancing human cognition with cocoa flavonoids. Front Nutr 2017; 4(May): 19.
[http://dx.doi.org/10.3389/fnut.2017.00019] [PMID: 28560212]
[56]
Grassi D, Ferri C, Desideri G. Brain protection and cognitive function: Cocoa flavonoids as nutraceuticals. Curr Pharm Des 2016; 22(2): 145-51.
[http://dx.doi.org/10.2174/1381612822666151112145730] [PMID: 26561075]
[57]
Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: A meta-analysis. J Am Med Dir Assoc 2017; 18(6): 503-8.
[http://dx.doi.org/10.1016/j.jamda.2016.12.071] [PMID: 28236605]
[58]
Al Karawi D, Al Mamoori DA, Tayyar Y. The role of curcumin administration in patients with major depressive disorder: Mini meta-analysis of clinical trials. Phytother Res 2016; 30(2): 175-83.
[http://dx.doi.org/10.1002/ptr.5524] [PMID: 26610378]
[59]
Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2015; 35(4): 406-10.
[http://dx.doi.org/10.1097/JCP.0000000000000352] [PMID: 26066335]
[60]
Seddon N, D’Cunha NM, Mellor DD, et al. Effects of curcumin on cognitive function—a systematic review of randomized controlled trials. Explor Res Hypothesis Med 2019; 4(1): 1-11.
[http://dx.doi.org/10.14218/ERHM.2018.00024]
[61]
Sharman J, Galeshi R, Onega L, Ashby S, Sharman K. The efficacy of curcumin on cognition, depression, and agitation in older adults with Alzheimer’s disease. Open Nutr J 2017; 11(1): 11-6.
[http://dx.doi.org/10.2174/1874288201711010011]
[62]
Zhu LN, Mei X, Zhang ZG, Xie YP, Lang F. Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis. Phytother Res 2019; 33(3): 524-33.
[http://dx.doi.org/10.1002/ptr.6257] [PMID: 30575152]
[63]
Fusar-Poli L, Vozza L, Gabbiadini A, et al. Curcumin for depression: A meta-analysis. Crit Rev Food Sci Nutr 2020; 60(15): 2643-53.
[http://dx.doi.org/10.1080/10408398.2019.1653260] [PMID: 31423805]
[64]
Chung MS, Kim GH. Effects of elsholtzia splendens and cirsium japonicum on premenstrual syndrome. Nutr Res Pract 2010; 4(4): 290-4.
[http://dx.doi.org/10.4162/nrp.2010.4.4.290] [PMID: 20827344]
[65]
Zhou ES, Gardiner P, Bertisch SM. Integrative medicine for insomnia. Med Clin North Am 2017; 101(5): 865-79.
[http://dx.doi.org/10.1016/j.mcna.2017.04.005] [PMID: 28802468]
[66]
Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: Role in mild cognitive impairment, dementia and depression. Ageing Res Rev 2015; 22: 9-19.
[http://dx.doi.org/10.1016/j.arr.2015.04.005] [PMID: 25939915]
[67]
Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr 2015; 27(5): 727-37.
[http://dx.doi.org/10.1017/S1041610215000046] [PMID: 25644193]
[68]
Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev 2016; 5(1): 148.
[http://dx.doi.org/10.1186/s13643-016-0325-2] [PMID: 27589952]
[69]
Humulus H, Bioactive M. HOP (Humulus). Westcott’s Plant Dis Handb 2008; pp. 910-0.
[70]
Smriga M, Ando T, Akutsu M, Furukawa Y, Miwa K, Morinaga Y. Oral treatment with L-lysine and L-arginine reduces anxiety and basal cortisol levels in healthy humans. Biomed Res 2007; 28(2): 85-90.
[http://dx.doi.org/10.2220/biomedres.28.85] [PMID: 17510493]
[71]
Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: Systematic review. Nutr J 2010; 9(1): 42.
[http://dx.doi.org/10.1186/1475-2891-9-42] [PMID: 20929532]
[72]
Pathol JC. Pdf 1984; 1984: 288-92.
[73]
Hidese S, Ota M, Wakabayashi C, et al. Effects of chronic l-theanine administration in patients with major depressive disorder: An open-label study. Acta Neuropsychiatr 2017; 29(2): 72-9.
[http://dx.doi.org/10.1017/neu.2016.33] [PMID: 27396868]
[74]
Emanuele E, Bertona M, Minoretti P, Geroldi D. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuroendocrinol Lett 2010; 31(5): 663-6.
[PMID: 21178946]
[75]
Ogawa S, Fujii T, Koga N, et al. Plasma L-tryptophan concentration in major depressive disorder: New data and meta-analysis. J Clin Psychiatry 2014; 75(9): e906-15.
[http://dx.doi.org/10.4088/JCP.13r08908] [PMID: 25295433]
[76]
Martínez-González MÁ, Magnesium Intake S-V A. Magnesium intake and depression: The sun. Cohort Magnes Res 16AD 29(3): 102-11.
[77]
Talbott SM, Talbott JA, Pugh M. Effect of Magnolia officinalis and Phellodendron amurense (Relora®) on cortisol and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr 2013; 10(1): 37.
[http://dx.doi.org/10.1186/1550-2783-10-37] [PMID: 23924268]
[78]
Rempel V, Fuchs A, Hinz S, et al. Magnolia Extract, magnolol, and metabolites: Activation of cannabinoid CB2 receptors and blockade of the related GPR55. ACS Med Chem Lett 2012; 4(1): 41-5.
[http://dx.doi.org/10.1021/ml300235q] [PMID: 24900561]
[79]
Zhang W, Chen XY, Su SW, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: A meta-analysis of randomized clinical trials. Neurol Sci 2016; 37(1): 57-65.
[http://dx.doi.org/10.1007/s10072-015-2357-0] [PMID: 26255301]
[80]
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: Melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8(5): e63773.
[http://dx.doi.org/10.1371/journal.pone.0063773] [PMID: 23691095]
[81]
Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am J Psychiatry 2016; 173(6): 575-87.
[http://dx.doi.org/10.1176/appi.ajp.2016.15091228] [PMID: 27113121]
[82]
Lin PY, Mischoulon D, Freeman MP, et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry 2012; 17(12): 1161-3.
[http://dx.doi.org/10.1038/mp.2012.111] [PMID: 22824812]
[83]
Pirbaglou M, Katz J, de Souza RJ, Stearns JC, Motamed M, Ritvo P. Probiotic supplementation can positively affect anxiety and depressive symptoms: A systematic review of randomized controlled trials. Nutr Res 2016; 36(9): 889-98.
[http://dx.doi.org/10.1016/j.nutres.2016.06.009] [PMID: 27632908]
[84]
Marx W, Moseley G, Berk M, Jacka F. Nutritional psychiatry: The present state of the evidence. Proc Nutr Soc 2017; 76(4): 427-36.
[http://dx.doi.org/10.1017/S0029665117002026] [PMID: 28942748]
[85]
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 2010; 17(7): 481-93.
[http://dx.doi.org/10.1016/j.phymed.2010.02.002] [PMID: 20378318]
[86]
Chiang HM, Chen HC, Wu CS, Wu PY, Wen KC. Rhodiola plants: Chemistry and biological activity. J Food Drug Anal 2015; 23(3): 359-69.
[http://dx.doi.org/10.1016/j.jfda.2015.04.007] [PMID: 28911692]
[87]
Amsterdam JD, Panossian AG. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine 2016; 23(7): 770-83.
[http://dx.doi.org/10.1016/j.phymed.2016.02.009] [PMID: 27013349]
[88]
Sharma A, Gerbarg P, Bottiglieri T, et al. S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinician-oriented review of research. J Clin Psychiatry 2017; 78(6): e656-67.
[http://dx.doi.org/10.4088/JCP.16r11113] [PMID: 28682528]
[89]
Sarris J, Price LH, Carpenter LL, et al. Is S-Adenosyl Methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized clinical trial. Pharmacopsychiatry 2015; 48(4-5): 141-4.
[http://dx.doi.org/10.1055/s-0035-1549928] [PMID: 26011569]
[90]
Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev 2015; 24: 1-12.
[http://dx.doi.org/10.1016/j.smrv.2014.12.003] [PMID: 25644982]
[91]
Becker A, Felgentreff F, Schröder H, Meier B, Brattström A. The anxiolytic effects of a Valerian extract is based on valerenic acid. BMC Complement Altern Med 2014; 14(1): 267.
[http://dx.doi.org/10.1186/1472-6882-14-267] [PMID: 25066015]
[92]
Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders-a systematic review and metaanalysis. J evidence-based Integr Med 2020. 25: 2515690X20967323.
[93]
Moretti M, Fraga DB, Rodrigues ALS. Ascorbic acid to manage psychiatric disorders. CNS Drugs 2017; 31(7): 571-83.
[http://dx.doi.org/10.1007/s40263-017-0446-8] [PMID: 28600627]
[94]
Amr M, El-mogy A, Shams T, Vieira K, Lakhan SE, Vita C. Trial MDD Children. Nutr J 2013; 12(31): 1-8.
[95]
Petrilli MA, Kranz TM, Kleinhaus K, et al. The emerging role for zinc in depression and psychosis. Front Pharmacol 2017; 8(JUN): 414.
[http://dx.doi.org/10.3389/fphar.2017.00414] [PMID: 28713269]
[96]
Orizio G, Schulz P, Domenighini S, et al. Cyberdrugs: A cross-sectional study of online pharmacies characteristics. Eur J Public Health 2009; 19(4): 375-7.
[http://dx.doi.org/10.1093/eurpub/ckn146] [PMID: 19151103]
[97]
Yoon SJ, Lyoo IK, Kim HJ, et al. Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5′-diphosphate choline: A longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2010; 35(5): 1165-73.
[http://dx.doi.org/10.1038/npp.2009.221] [PMID: 20043005]
[98]
Wezenberg E, Verkes RJ, Ruigt GSF, Hulstijn W, Sabbe BGC. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007; 32(6): 1272-83.
[http://dx.doi.org/10.1038/sj.npp.1301257] [PMID: 17119538]
[99]
Talih F, Ajaltouni J. Probable nootropicinduced psychiatric adverse effects: A series of four cases. Innov Clin Neurosci 2015; 12(11-12): 21-5.
[PMID: 27222762]
[100]
Clarke S, Savulescu J, Coady CA, Giubilini A. S S The Ethics of Human Enhancement: Understanding the Debate. Oxford University Press 2016.
[http://dx.doi.org/10.1093/acprof:oso/9780198754855.001.0001]
[101]
Lavazza A. Transcranial electrical stimulation for human enhancement and the risk of inequality: Prohibition or compensation? Bioethics 2019; 33(1): 122-31.
[http://dx.doi.org/10.1111/bioe.12504] [PMID: 30157289]
[102]
Ricci G. Pharmacological human enhancement: An overview of the looming bioethical and regulatory challenges. Front Psychiatry 2020; 11(February): 53.
[http://dx.doi.org/10.3389/fpsyt.2020.00053] [PMID: 32127792]
[103]
Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: Old fashioned, but still in vogue. Front Psychiatry 2014; 5(APR): 47.
[PMID: 24904434]
[104]
Horder J, Petrinovic MM, Mendez MA, et al. Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models. Transl Psychiatry 2018; 8(1): 106.
[http://dx.doi.org/10.1038/s41398-018-0155-1] [PMID: 29802263]
[105]
Tse TJ, Reaney MJT. Enrichment and utilization of thin stillage by‐products. Food Wastes By‐products 2020; pp. 35-57.
[106]
Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr 2015; 12(1): 42.
[http://dx.doi.org/10.1186/s12970-015-0103-x] [PMID: 26582972]
[107]
Narayanan R, Gilbert B, Ravichandran S, Bhuvaneswari K. Psychopharmacological characterization of effects of Ferula asafoetida linn. Formulation in Mouse on a Y-Maze, EPM, and open field apparatus. Int J Basic Clin Pharmacol 2017; 6(9): 2254.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20173755]
[108]
Mhillaj E, Catino S, Miceli FM, et al. Ferulic acid improves cognitive skills through the activation of the heme oxygenase system in the rat. Mol Neurobiol 2018; 55(2): 905-16.
[http://dx.doi.org/10.1007/s12035-017-0381-1] [PMID: 28083818]
[109]
Mancuso C, Santangelo R. Ferulic acid: Pharmacological and toxicological aspects. Food Chem Toxicol 2014; 65: 185-95.
[http://dx.doi.org/10.1016/j.fct.2013.12.024] [PMID: 24373826]
[110]
Sellés MC, Fortuna J, Cercato M, et al. Neuronal expression of NUsc1, a single-chain variable fragment antibody against ab oligomers, protects synapses and rescues memory in alzheimer’s disease models. IBRO Rep 2019; 6(1): S497.
[http://dx.doi.org/10.1016/j.ibror.2019.07.1558]
[111]
Chu Y, Bartus RT, Manfredsson FP, Olanow CW, Kordower JH. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease. Brain 2020; 143(3): 960-75.
[http://dx.doi.org/10.1093/brain/awaa020] [PMID: 32203581]
[112]
Chiroma SM, Taib CNM, Moklas MAM, Baharuldin MTH, Amom Z, Jagadeesan S. The use of nootropics in alzheimer’s disease: Is there light at the end of the tunnel? Biomed Res Ther 2019; 6(1): 2937-44.
[http://dx.doi.org/10.15419/bmrat.v6i1.513]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy